| Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression (NCT04957615) | M.D. Anderson Cancer Center | 2021-09-21 |
| Study of GNX102 in Patients With Advanced Solid Tumors (NCT04250597) | GlycoNex, Inc. | 2020-07-29 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors (NCT03366103) | National Cancer Institute (NCI) | 2018-03-20 |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction (NCT03217253) | National Cancer Institute (NCI) | 2018-03-16 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma (NCT03061188) | Northwestern University | 2017-05-23 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery (NCT03087591) | Wake Forest University Health Sciences | 2017-04-28 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732) | M.D. Anderson Cancer Center | 2016-08-15 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (NCT02535312) | National Cancer Institute (NCI) | 2016-03-08 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861) | National Cancer Institute (NCI) | 2015-10-21 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401) | National Cancer Institute (NCI) | 2015-01-30 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (NCT02070549) | National Cancer Institute (NCI) | 2014-03-10 |
| Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus (NCT01822522) | National Cancer Institute (NCI) | 2013-06-21 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139) | M.D. Anderson Cancer Center | 2013-02-19 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (NCT01012817) | National Cancer Institute (NCI) | 2009-11-03 |